Cargando…
Identification of NOX4 as a New Biomarker in Hepatocellular Carcinoma and Its Effect on Sorafenib Therapy
To improve the survival of patients with hepatocellular carcinoma (HCC), new biomarkers and therapeutic targets are urgently needed. In this study, the GEO and TCGA dataset were used to explore the differential co-expressed genes and their prognostic correlation between HCC and normal samples. The m...
Autores principales: | Li, Hui-Zhou, Liu, Qing-Qing, Chang, De-Hua, Li, Shu-Xian, Yang, Long-Tao, Zhou, Peng, Deng, Jiang-Bei, Huang, Chang-Hao, Xiao, Yu-Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452076/ https://www.ncbi.nlm.nih.gov/pubmed/37626693 http://dx.doi.org/10.3390/biomedicines11082196 |
Ejemplares similares
-
Serum hsa_circ_0000615 is a prognostic biomarker of sorafenib resistance in hepatocellular carcinoma
por: Zhang, Lunjun, et al.
Publicado: (2022) -
Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis
por: Huang, Danping, et al.
Publicado: (2018) -
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016) -
Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy
por: Shao, Mingyang, et al.
Publicado: (2023) -
PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma
por: Wang, Pusen, et al.
Publicado: (2020)